William Hrushesky to Hematinics
This is a "connection" page, showing publications William Hrushesky has written about Hematinics.
Connection Strength
0.745
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
Score: 0.169
-
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
Score: 0.164
-
End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
Score: 0.160
-
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
Score: 0.132
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
Score: 0.120